Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$3.26
-0.10-2.98%
At close: May 18, 5:00 PM EST
$3.66
0.4012.27%
After Hours: 9:27 AM EST
Can Fite Biopharma Ltd Analyst Ratings
CANFAMEX
Can Fite Biopharma Analyst Ratings and Price Targets | AMEX:CANF | Benzinga
Can Fite Biopharma Ltd has a consensus price target of $10 based on the ratings of 4 analysts. The high is $18 issued by HC Wainwright & Co. on November 12, 2024. The low is $5 issued by HC Wainwright & Co. on May 12, 2026. The 3 most-recent analyst ratings were released by D. Boral Capital, HC Wainwright & Co., and D. Boral Capital on May 13, 2026, May 12, 2026, and December 17, 2025, respectively. With an average price target of $5.33 between D. Boral Capital, HC Wainwright & Co., and D. Boral Capital, there's an implied 45.72% upside for Can Fite Biopharma Ltd from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
D. Boral Capital
HC Wainwright & Co.
HC Wainwright & Co.
EF Hutton
1calculated from analyst ratings
Analyst Ratings for Can Fite Biopharma
Loading calendar...
FAQ
What is the target price for Can Fite Biopharma (CANF) stock?
The latest price target for Can Fite Biopharma (AMEX:CANF) was reported by D. Boral Capital on May 13, 2026. The analyst firm set a price target for $7.00 expecting CANF to rise to within 12 months (a possible 91.26% upside). 9 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Can Fite Biopharma (CANF)?
The latest analyst rating for Can Fite Biopharma (AMEX:CANF) was provided by D. Boral Capital, and Can Fite Biopharma upgraded their buy rating.
When was the last upgrade for Can Fite Biopharma (CANF)?
The last upgrade for Can Fite Biopharma Ltd happened on May 13, 2026 when D. Boral Capital raised their price target to $7. D. Boral Capital previously had a hold for Can Fite Biopharma Ltd.
When was the last downgrade for Can Fite Biopharma (CANF)?
The last downgrade for Can Fite Biopharma Ltd happened on December 24, 2025 when D. Boral Capital changed their price target from N/A to N/A for Can Fite Biopharma Ltd.
When is the next analyst rating going to be posted or updated for Can Fite Biopharma (CANF)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Can Fite Biopharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Can Fite Biopharma was filed on May 13, 2026 so you should expect the next rating to be made available sometime around May 13, 2027.
Is the Analyst Rating Can Fite Biopharma (CANF) correct?
While ratings are subjective and will change, the latest Can Fite Biopharma (CANF) rating was a upgraded with a price target of $0.00 to $7.00. The current price Can Fite Biopharma (CANF) is trading at is $3.66, which is within the analyst’s predicted range.
